There are 2789 resources available
946P - Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage C: A prospective, single-arm, phase II trial (TRIPLET study)
Presenter: Tian-Qi Zhang
Session: ePoster Display
947P - Updated survival and secondary safety and efficacy analyses from CA 209-678: A phase II open-label single-centre study of Y90-radioembolisation (Y90) in combination with nivolumab in Asian patients (pts) with advanced hepatocellular carcinoma (aHCC)
Presenter: Joycelyn Lee
Session: ePoster Display
948P - Predicting the efficacy of lenvatinib plus anti-PD-1 antibodies in unresectable hepatocellular carcinoma (uHCC) using radiomics features of tumors extracted from baseline MRI
Presenter: Huichuan Sun
Session: ePoster Display
949P - Thermal ablation plus toripalimab in patients with advanced hepatocellular carcinoma: Phase I results from a multicenter, open-label, controlled phase I/II trial (IR11330)
Presenter: Liangrong Shi
Session: ePoster Display
950P - Ultra-sensitive and cost-effective method for early stage hepatocellular carcinoma and intrahepatic cholangiocarcinoma detection using plasma cfDNA fragmentomic profiles
Presenter: Xiangyu Zhang
Session: ePoster Display
951P - Application of deep learning on whole-slide images to predict relapse-free survival of hepatocellular carcinoma patients following liver transplant
Presenter: Daniel Roberts
Session: ePoster Display
952P - Prognostic implication of serum alpha-fetoprotein in patients with unresectable hepatocellular carcinoma treated with regorafenib
Presenter: Dong-Hoon Lim
Session: ePoster Display
953P - Trends in disease burden from hepatocellular carcinoma: An observational study of European union 15+ countries
Presenter: Georgina Hanbury
Session: ePoster Display
954P - Comparison of medical costs and outcome between hepatectomy and radiofrequency ablation for hepatocellular carcinoma
Presenter: Takeshi Terashima
Session: ePoster Display
955P - Prognostic factor analysis of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: Korean cancer study group (KCSG) study
Presenter: Jaekyung Cheon
Session: ePoster Display